¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Hq$?-%4  
V5LzUg]  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© G_x<2E"d  
Go_~8w0<  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© UYb:q  
co%ttH\ n  
1.Co-stimulators (or co-stimulating molecules) ] Vbv64M3  
F\;G'dm  
2.NK-kB {)0"?$C_H  
Hi<5jl  
3.Immunoglobulin superfamily t|aBe7t7  
vN%SN>=L<  
4.antigen-presenting cell (APC) g k[ 8'  
h~ =UFE%'  
5.death domain @ zE>n  
/_P5U E(  
6.CCR and CXCR y++[:M  
<x),HTJ  
7.Lectin (or mitogen) :  )\<  
=5jX#Dc5.+  
8.Clusters of differentiation, CD) >I3#ALF  
G~I@'[ur  
9.B7 family gI qYIt  
c?{&=,u2  
10.Cytotoxic T lymphocyte, CTL) ~ b ;%J:  
g,!6, v@  
11.IL-15 and IL-15 receptor (IL-15R) jLf.qf8qm  
*;wPAQE  
12.MHC restriction R*D0A@  
~JsTHE$F  
13.Affinity-chromatography ~ FW@  
2 Ke?*  
14.Cyctosprin A, CsA wG4=[d  
p*8LS7UT  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) YT6<1-E#  
:e 5)Q=lX  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© {i)k#`  
~*9 vn Z@  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 *4;MO2g  
E-_FxBw  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ L<encPJt  
NWuS/Ur`9  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ |T~C($9  
Y#EM]x5!=  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© }u0t i"V  
/pZ]:.A  
ÃâÒßѧרҵ£º 4i>sOP3 B  
)2KQZMtgm]  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ y-qbK0=X4  
*P,dR]-m  
Ïû»¯ÄÚ¿Æ£º lL.3$Rp;  
h=uwOi6}  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ M[N$N`9  
LwQq0<v  
ѪҺ²¡Ñ§×¨Òµ£º 8y5iT?.~vy  
O)78 iEXi|  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»